The International
LungCancerSummit
Where Leaders in Thoracic Oncology UniteAgainst Lung Cancer||To Share Knowledge||To Exchange||To Debate||To Advance Care||To Fight Cancer||To Drive Progress||To Provide Insights
Your invitation · 2 min
A word from our faculty
Led by global experts
The people in the room
A global roster of oncologists, surgeons and pathologists, chaired from Lausanne and drawn from across the field.
David Planchard
France
Alessio Cortellini
Italy
Alfredo Addeo
Chair, Switzerland
Hidehito Horinouchi
Japan
Millie Das
USA
Giannis Mountzios
Greece
Christine Lovly
USA
Sandip Patel
USA
Nikolaj Frost
Germany
Anne-Marie Dingemans
Netherlands
Telma Sequeira
Portugal
Solange Peters
Chair, Switzerland
ILCS 2026 on demand · 13 Nov 2026
CME-certified
Expert-Driven Education & Insights
A day built around what changes practice
Latest options in early-stage NSCLC: novel IO approaches for improved outcomes
Sandip PatelFirst-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C
Alessandra Curioni-FontecedroWatch the recording
One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey
Maximilian HochmairWatch the recording
Watch ILCS 2026 on demand
Free for registered healthcare professionals · every talk, the debate and the panel
Accreditation
5 + 5 CME credits
Accredited by UEMS–EACCME & the Swiss Society of Medical Oncology
Save the date · Friday, 1 October 2027
ILCS 2027 in Lausanne
The International Lung Cancer Summit returns next year, at CHUV in Lausanne and live-streamed worldwide. Put it in your calendar now.
ILCS · In frames
Last year in Lausanne: the ILCS 2025 gallery
A day on the ground with the faculty, the debate and the room between sessions.
Partners & supporters
Backed, independently
The ILCS is supported by 21 industry partners, with no influence on the content.
For sponsoring opportunities, please contact us at sponsors@lungsummit.org
Beyond the summit
Year-round education
The summit doesn’t stop in November. Watch every ILCS session on demand, plus webinars, expert debates and interviews, released all year and CME-certified.
Live & upcoming
Upcoming events
Live symposia, webinar series and new interviews between summits, released and CME-certified all year.
Coming soon · 17:00 CET
2026 Year in Review
Speakers
Agenda & discussion topics
Druggable Since 2026: New Approvals and Emerging Options
The Paradigm Shift in SCLC: From Hope to Practice
Highlights in Targeted Therapies and ADCsChoose your calendar
Google Calendar (Online)
Outlook Calendar (Offline)
Outlook On Microsoft Office 365 (Online)
Outlook On The Web (Online)
Apple Offline Calendar / iCalThe library
Watch on demand
Featured sessions
Expert Insights
The Reading Room
MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells
Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC
Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling
KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC
VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
Community indicators flagged high lung cancer incidence areas in California better than smoking alone
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
Watch every session on demand
Free for healthcare professionals. One account opens every session, webinar and interview.
Find your area
Browse by topic
Patient Cases
Let us discuss your patient in our expert roundtables
Submit an anonymised case or a question. The faculty take it up live at our webinars and at ILCS. The questions you carry into clinic, answered by the people writing the guidelines.
Stay in the room
Join our network in thoracic oncology
One email when there is something new. Sessions, the next roundtable, the next live event.